BE2013C045I2 - - Google Patents

Download PDF

Info

Publication number
BE2013C045I2
BE2013C045I2 BE2013C045C BE2013C045C BE2013C045I2 BE 2013C045 I2 BE2013C045 I2 BE 2013C045I2 BE 2013C045 C BE2013C045 C BE 2013C045C BE 2013C045 C BE2013C045 C BE 2013C045C BE 2013C045 I2 BE2013C045 I2 BE 2013C045I2
Authority
BE
Belgium
Prior art keywords
protein
large aggregates
conjugates
essentially
uricase
Prior art date
Application number
BE2013C045C
Other languages
English (en)
Original Assignee
Mountain View Pharmaceuticals Inc
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountain View Pharmaceuticals Inc, Univ Duke filed Critical Mountain View Pharmaceuticals Inc
Publication of BE2013C045I2 publication Critical patent/BE2013C045I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
BE2013C045C 2000-02-10 2013-07-03 BE2013C045I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/501,730 US6783965B1 (en) 2000-02-10 2000-02-10 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PCT/US2001/040069 WO2001059078A2 (fr) 2000-02-10 2001-02-07 Urate oxidase exempte d"agregats destinee a la preparation de conjugues de polymere immunogenes
EP01923265A EP1254237B1 (fr) 2000-02-10 2001-02-07 Urate oxidase exempte d'agrégats destinée a la préparation de polymères conjugués non-immunogènes

Publications (1)

Publication Number Publication Date
BE2013C045I2 true BE2013C045I2 (fr) 2020-06-24

Family

ID=23994789

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C045C BE2013C045I2 (fr) 2000-02-10 2013-07-03

Country Status (28)

Country Link
US (3) US6783965B1 (fr)
EP (3) EP1254237B1 (fr)
JP (2) JP5165826B2 (fr)
KR (3) KR20070092329A (fr)
CN (2) CN101735991B (fr)
AT (1) ATE463576T1 (fr)
AU (3) AU2001249975B2 (fr)
BE (1) BE2013C045I2 (fr)
BR (1) BRPI0108386B8 (fr)
CA (1) CA2398679C (fr)
CY (3) CY1110142T1 (fr)
CZ (1) CZ304864B6 (fr)
DE (1) DE60141742D1 (fr)
DK (3) DK2305819T3 (fr)
ES (2) ES2343105T3 (fr)
FR (1) FR13C0036I2 (fr)
HK (4) HK1056742A1 (fr)
HU (1) HU227127B1 (fr)
IL (3) IL151065A0 (fr)
LU (1) LU92237I2 (fr)
MX (1) MXPA02007545A (fr)
NZ (1) NZ520434A (fr)
PL (1) PL208064B1 (fr)
PT (2) PT2305819E (fr)
RU (3) RU2352354C2 (fr)
TW (2) TW200914617A (fr)
WO (1) WO2001059078A2 (fr)
ZA (1) ZA200207206B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP2277998B1 (fr) 1998-08-06 2016-04-20 Duke University Urate oxydase
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
NZ509595A (en) * 1998-08-06 2004-02-27 Univ Duke Peg-urate oxidase conjugates and use thereof
PT1100542E (pt) 1998-08-06 2005-11-30 Mountain View Pharmaceuticals Conjugado de peg-uricase oxidase e seu uso
DE60229958D1 (de) 2001-06-28 2009-01-02 Mountain View Pharmaceuticals Polymerstabilisierte proteinasen
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
MXPA05006944A (es) * 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de interferon-beta cion potencia biologica aumentada.
BRPI0411160A (pt) * 2003-05-12 2006-07-11 Affymax Inc novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
JP4949844B2 (ja) * 2003-05-12 2012-06-13 アフィーマックス・インコーポレイテッド エリスロポエチン受容体に結合する新規ペプチド
EP1628686A2 (fr) * 2003-05-12 2006-03-01 Affymax, Inc. Fragment espaceur de peptides modifies par du poly (ethylene glycol)
DK1663281T3 (en) * 2003-08-29 2014-03-17 Dyax Corp POLY-PEGYLED PROTEASE INHIBITORS
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20090005292A1 (en) * 2004-11-11 2009-01-01 Affymax, Inc. Novel Peptides that Bind to the Erythropoietin Receptor
WO2006062685A2 (fr) * 2004-11-11 2006-06-15 Affymax, Inc. Nouveaux peptides se liant au recepteur de l'erythropoietine
EP2314320A2 (fr) * 2005-04-05 2011-04-27 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Procédé de protection de sites fonctionnels ou épitopes sur des protéines
EP2918676B1 (fr) 2005-04-11 2018-01-31 Crealta Pharmaceuticals LLC Variante d'urate oxydase et son utilisation
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
NZ562292A (en) 2005-04-11 2009-11-27 Savient Pharmaceuticals Inc Variant forms of urate oxidase and use thereof
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2006125452A1 (fr) * 2005-05-23 2006-11-30 Universite De Geneve Nanoparticules superparamagnetiques injectables destinees a un traitement par hyperthermie et a la formation d'un implant
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
JP5033177B2 (ja) * 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク． 陽イオン界面活性剤によるタンパク質の精製
WO2009026334A2 (fr) * 2007-08-21 2009-02-26 Genzyme Corporation Traitement par des inhibiteurs de la kallikréine
WO2010080833A1 (fr) 2009-01-06 2010-07-15 Dyax Corp. Traitement de la mucosite par des inhibiteurs de kallikréine
CA2766309A1 (fr) 2009-06-25 2010-12-29 Savient Pharmaceuticals, Inc. Procedes et necessaires pour predire un risque de reaction a la perfusion et une perte de reponse mediee par des anticorps par surveillance de l'acide urique serique pendant un traitement a l'uricase pegylee
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
US8940861B2 (en) 2010-04-08 2015-01-27 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
CA2823776A1 (fr) 2011-01-06 2012-07-12 Dyax Corp. Proteines se liant a la kallikreine plasmatique
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US11077238B2 (en) * 2013-06-07 2021-08-03 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
CA2917671A1 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composes de 2,4 ou de 4,6-diaminopyrimidine en tant qu'inhibiteurs des mutants idh2 pour le traitement du cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
WO2015003355A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
JP6564796B2 (ja) 2014-03-14 2019-08-21 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物の医薬組成物
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
EP3294322A4 (fr) 2015-05-15 2018-12-12 Medimmune, LLC Séquences d'uricase améliorées et méthodes de traitement
PT3362066T (pt) 2015-10-15 2021-11-16 Celgene Corp Terapia de combinação para tratar malignidades
CA3216701A1 (fr) 2015-10-15 2017-04-20 Les Laboratoires Servier Polytherapie pour le traitement de malignites
EA201891388A1 (ru) 2015-12-11 2018-11-30 Дайэкс Корп. Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
EP3655527A4 (fr) 2017-07-07 2021-06-16 Allena Pharmaceuticals Inc. Enzyme uricase recombinante
WO2019183292A1 (fr) 2018-03-20 2019-09-26 Rubius Therapeutics, Inc. Systèmes de cellules thérapeutiques et méthodes de traitement de l'hyperuricémie et de la goutte
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN109055260B (zh) * 2018-08-08 2021-11-09 淮海工学院 弯曲芽孢杆菌alkaAU及产尿酸氧化酶方法、产品与应用
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (fr)
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
CH651308A5 (de) 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
EP0229108B1 (fr) * 1985-06-26 1990-12-27 Cetus Corporation Solubilisation de proteines pour des compositions pharmaceutiques utilisant une conjugaison de polymeres
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
JPH085506B2 (ja) * 1986-08-25 1996-01-24 日東製器株式会社 缶容器
DD279489A1 (de) 1986-12-11 1990-06-06 Leuna Werke Veb Verfahren zur herstellung optisch transparenter epoxidharzformmassen
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5955336A (en) * 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
KR0159107B1 (ko) 1989-07-13 1998-11-16 쟝 르쌍드뢰 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
ES2199935T3 (es) * 1991-03-15 2004-03-01 Amgen Inc. Pegilacion de polipeptidos.
EP0940154B1 (fr) 1991-07-02 2007-04-18 Nektar Therapeutics Dispositif pour administrer des aérosols de médicaments
AU6240494A (en) 1993-02-16 1994-09-14 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
WO1994023740A1 (fr) * 1993-04-22 1994-10-27 Celtrix Pharmaceuticals, Inc. Conjugues du facteur de croissance et d'inhibiteur de la resorption osseuse
WO1995000162A1 (fr) 1993-06-21 1995-01-05 Enzon, Inc. Synthese de peptides conjuges modifies, sur des sites specifiques
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
EP0730470B1 (fr) 1993-11-10 2002-03-27 Enzon, Inc. Produits de conjugaison ameliores d'un interferon avec un polymere
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
MX9704137A (es) 1994-12-07 1997-09-30 Novo Nordisk As Polipeptidos de alergenicidad reducida.
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US5853974A (en) 1995-06-07 1998-12-29 Chiron Corporation Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
DE69836222T2 (de) 1997-01-15 2007-11-15 Phoenix Pharmacologics, Inc. Modifizierter tumor-nekrosefaktor
EP1084136B1 (fr) * 1998-06-01 2004-08-25 Genentech, Inc. Separation des monomeres d'un anticorps de ses multimeres par l'utilisation de la chromatographie echangeuse d'ions
NZ509595A (en) 1998-08-06 2004-02-27 Univ Duke Peg-urate oxidase conjugates and use thereof
PT1100542E (pt) * 1998-08-06 2005-11-30 Mountain View Pharmaceuticals Conjugado de peg-uricase oxidase e seu uso
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP2277998B1 (fr) 1998-08-06 2016-04-20 Duke University Urate oxydase
US6425448B1 (en) 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
EP3005545A1 (fr) 2013-05-24 2016-04-13 Zentrum Mikroelektronik Dresden AG Convertisseur continu - continu numérique non pwm

Also Published As

Publication number Publication date
CN100491532C (zh) 2009-05-27
EP2305819B1 (fr) 2014-11-12
PT2305819E (pt) 2015-06-01
EP2196538A1 (fr) 2010-06-16
RU2281954C2 (ru) 2006-08-20
CZ304864B6 (cs) 2014-12-17
RU2009104003A (ru) 2010-08-20
IL193365A0 (en) 2009-02-11
PL208064B1 (pl) 2011-03-31
PT1254237E (pt) 2010-06-07
DK1254237T3 (da) 2010-07-19
KR20020087934A (ko) 2002-11-23
RU2557318C2 (ru) 2015-07-20
CN1423699A (zh) 2003-06-11
FR13C0036I2 (fr) 2014-05-16
KR101054247B1 (ko) 2011-08-08
LU92237I2 (fr) 2013-09-03
AU2009212900A1 (en) 2009-10-01
AU2001249975B2 (en) 2006-06-08
HK1144701A1 (en) 2011-03-04
MXPA02007545A (es) 2002-12-13
HUP0204544A2 (en) 2003-05-28
AU4997501A (en) 2001-08-20
FR13C0036I1 (fr) 2013-08-09
US7927852B2 (en) 2011-04-19
NZ520434A (en) 2004-05-28
EP1254237B1 (fr) 2010-04-07
JP5341945B2 (ja) 2013-11-13
CN101735991B (zh) 2013-09-11
BR0108386A (pt) 2002-10-29
KR20080098686A (ko) 2008-11-11
CY2013028I1 (el) 2015-11-04
BR0108386C1 (pt) 2011-12-20
EP2196538B1 (fr) 2014-10-01
BR0108386B1 (pt) 2017-10-31
CY1117264T1 (el) 2017-04-26
CN101735991A (zh) 2010-06-16
CZ20022982A3 (cs) 2003-01-15
TW200914617A (en) 2009-04-01
WO2001059078A2 (fr) 2001-08-16
HUP0204544A3 (en) 2007-05-02
BRPI0108386B8 (pt) 2021-05-25
HU227127B1 (en) 2010-07-28
IL193365A (en) 2011-08-31
RU2006107110A (ru) 2007-09-20
HK1056742A1 (en) 2004-02-27
HK1143989A1 (en) 2011-01-21
RU2557318C9 (ru) 2015-09-10
IL151065A0 (en) 2003-04-10
US20110287466A1 (en) 2011-11-24
EP2305819A1 (fr) 2011-04-06
KR20070092329A (ko) 2007-09-12
RU2352354C2 (ru) 2009-04-20
KR100884724B1 (ko) 2009-02-19
DK2196538T3 (en) 2015-01-05
HK1155203A1 (en) 2012-05-11
JP2003521937A (ja) 2003-07-22
ES2343105T8 (es) 2013-07-15
US6783965B1 (en) 2004-08-31
CA2398679A1 (fr) 2001-08-16
CA2398679C (fr) 2015-11-17
TWI322184B (en) 2010-03-21
PL358539A1 (en) 2004-08-09
CY2013028I2 (el) 2015-11-04
US20080057048A1 (en) 2008-03-06
CY1110142T1 (el) 2015-01-14
ZA200207206B (en) 2003-05-06
EP1254237A2 (fr) 2002-11-06
IL151065A (en) 2008-12-29
JP2011188861A (ja) 2011-09-29
WO2001059078A3 (fr) 2002-03-07
ATE463576T1 (de) 2010-04-15
DE60141742D1 (de) 2010-05-20
AU2009212900B2 (en) 2011-12-08
DK2305819T3 (en) 2015-01-05
JP5165826B2 (ja) 2013-03-21
ES2343105T3 (es) 2010-07-23
ES2524153T3 (es) 2014-12-04
US8921064B2 (en) 2014-12-30

Similar Documents

Publication Publication Date Title
BE2013C045I2 (fr)
KR940019312A (ko) 폴리에틸렌 옥사이드로 개질된 단백질 및 폴리펩티드와 사이클로덱스트린의 동결 건조된 복합체
HK1076115A1 (en) Polyol-ifn-beta conjugates
WO2002002143A3 (fr) Renforcement des reponses immunitaires dont la mediation est assuree par une proteine de fusion anticorp-cytokine via le traitement combine a base d'agents ameliorant la fixation des immunocytokines
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
PT1100542E (pt) Conjugado de peg-uricase oxidase e seu uso
CA2064689A1 (fr) Conjugues de proteines ou de peptides stabilises
BR0211071A (pt) Conjugado polipeptìdico apresentando atividade de g-csf, método para preparar um conjugado de g-csf, composição, método para tratar um mamìfero sofrendo de um nìvel neutrofìlico insuficiente, e, uso do conjugado polipeptìdico
NZ509595A (en) Peg-urate oxidase conjugates and use thereof
AU2236795A (en) Afamin: a human serum albumin-like protein
DE60223232D1 (de) Mucinpeptid mit immunstärkenden eigenschaften
TW200619386A (en) Polyol-IFN-beta conjugates
Yuecel et al. Increased susceptibility to oxidative stress in lens tissues of sulfur dioxide exposed rats
AU2002300605A1 (en) Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods